Physician profile
Tina Pai
NPI 1972630366
$3,610.37
in general payments reported to CMS, 2019-2025
8 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $56.25 · 2021: $316 · 2022: $338 · 2023: $320 · 2024: $873 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,332.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,165.65 | 2023-2025 | |
| Allergan, INC. | $1,092.10 | 2019-2022 | |
| Revance Therapeutics, INC. | $1,064.76 | 2024-2025 | Daxxify, Daxi |
| Galderma Laboratories, L.P. | $103.98 | 2021-2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $103.31 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.41 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $28.99 | 2021 | |
| Biofrontera INC. | $16.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Pai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.